Press Releases
Site - Investor Relations
In
Besides the synergies already present with our
zPREDICTA brings a historical revenue stream and profitable bottom-line to POAI. Coupled with our anticipated commercialization of our Discovery 21 project, POAI is emerging from a research and development-only company to a biopharmaceutical revenue-based company.
To support our commercialization efforts, POAI announced the hiring of
Working together, we endeavor to eliminate cancer while simultaneously providing strong returns to our investors.
Thank you,
About
As the drug discovery community has now realized, a genomics-based approach to cancer research and drug development is insufficient to achieve the promise of personalized therapeutics.
Forward-Looking Statements: Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, risks related to the acquisition of zPREDICTA including no assurance of future operating results of zPREDICTA, no assurance that zPREDICTA’s customers will continue to utilize zPREDICTA’s services at historical levels or at all, risk of higher than anticipated expenses, integration risk, risk of future impairment of goodwill that would impact POAI’s operating results and reliance on zPREDICTA’s management and employees, and the factors discussed under the heading “Risk Factors” in our filings with the
Investor Relations Contact:
Landon Capital
kpinder@landoncapital.net
Source: Predictive Oncology Inc.